Duopharma Biotech Bhd
KLSE:DPHARMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Duopharma Biotech Bhd
Total Receivables
Duopharma Biotech Bhd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Duopharma Biotech Bhd
KLSE:DPHARMA
|
Total Receivables
235.4m
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
|
P
|
PeterLabs Holdings Bhd
KLSE:PLABS
|
Total Receivables
27.1m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
A
|
Apex Healthcare Bhd
KLSE:AHEALTH
|
Total Receivables
202.7m
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
R
|
Rhone Ma Holdings Bhd
KLSE:RHONEMA
|
Total Receivables
43.1m
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Y
|
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
|
Total Receivables
104.5m
|
CAGR 3-Years
15%
|
CAGR 5-Years
10%
|
CAGR 10-Years
6%
|
|
|
K
|
Kotra Industries Bhd
KLSE:KOTRA
|
Total Receivables
42m
|
CAGR 3-Years
0%
|
CAGR 5-Years
9%
|
CAGR 10-Years
0%
|
|
Duopharma Biotech Bhd
Glance View
Duopharma Biotech Bhd.is an investment holding company, which engages in the manufacturing and distribution of pharmaceutical products. The company is headquartered in Klang, Selangor. The company went IPO on 2002-07-18. The Company, through its subsidiaries is engaged in manufacturing, distribution, importing and exporting of pharmaceutical products and medicines. The firm also engaged in research and development of pharmaceutical products. Its subsidiaries include Duopharma (M) Sendirian Berhad, Duopharma Manufacturing (Bangi) Sdn. Bhd., Duopharma Marketing Sdn. Bhd., Duopharma Consumer Healthcare Sdn. Bhd., Duopharma HAPI Sdn. Bhd., Duopharma Innovation Sdn. Bhd., Unique Pharmacy (Penang) Sdn. Bhd., Sentosa Pharmacy Sdn. Bhd., Duopharma Manufacturing (Glenmarie) Sdn. Bhd., Negeri Pharmacy Sdn. Bhd., Duopharma (Singapore) Pte. Ltd. and DB (Philippines), Inc.
See Also
What is Duopharma Biotech Bhd's Total Receivables?
Total Receivables
235.4m
MYR
Based on the financial report for Dec 31, 2025, Duopharma Biotech Bhd's Total Receivables amounts to 235.4m MYR.
What is Duopharma Biotech Bhd's Total Receivables growth rate?
Total Receivables CAGR 10Y
8%
Over the last year, the Total Receivables growth was 10%. The average annual Total Receivables growth rates for Duopharma Biotech Bhd have been 17% over the past three years , 9% over the past five years , and 8% over the past ten years .
